$XTALPI(02228.HK) The single-arm trial is also about to enter Phase II! The kick-off meeting for the National Science and Technology Major Project on "Mechanism Analysis of Refractory Gastric Cancer and Application of New Target Small Molecule Drug R&D" will be officially held at Peking University Cancer Hospital. As a core participating unit, Xige Shengke was invited to attend and will report preliminary results and latest progress of the project to the expert guidance group led by Prof. Shen Lin. SIGX1094, the world's first targeted therapy for diffuse gastric cancer developed by Xige Shengke based on its "organoid + AI" platform, has been granted orphan drug designation and fast track qualification by the US FDA, and received a nomination for the Galen Prize in 2025, known as the "Nobel Prize of the pharmaceutical industry." The clinical Phase I trial for this drug is being successfully conducted under the leadership of Prof. Shen Lin's team at Peking University Cancer Hospital and is about to enter the next phase.